Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	HGN

1 year chart

1 day chart

Halcygen Pharmaceuticals Limited
HalcyGen Pharmaceuticals Limited focuses to bring reformulated existing drugs to the market, known as SuperGenerics. The Company has two development programmes: SUBA-itraconazole and Minocycline. SUBA-itraconazole is a bioavailable formulation of itraconazole, a synthetic broad-spectrum anti-fungal agent. Minocycline is a member of the tetracycline antibiotic family. Minocycline is used to treat bacterial infections, including pneumonia and other respiratory tract infections, acne and infections of skin, genital, and urinary systems. It can also be used to eliminate bacteria from the nose and throat.

Halcygen files for registration of anti-fungal product, SUBA-Itraconazole

Friday, August 28, 2009

Developer of improved variants of existing proprietary pharmaceuticals known as super generics, HalcyGen Pharmaceuticals (ASX: HGN) has filed a registration of its anti-fungal product, known as SUBA-Itraconazole, in the EU.

Super generic drugs are reformulations of off-patent drugs and bridge the gap between mainline and pharmaceutical companies and high volume generics. They can often enjoy patent protected positions and have higher margins.

SUBA-Itraconazole is a "value added formulation" of the anti-fungal drug Sporanox®. The anti-fungal target market is a worldwide annual $600 million market. SUBA-Itraconazole has significant benefits relative to Sporanox®.

Dr Roger Aston chief executive officer of HalcyGen said the company is working on appointing marketing and distribution partners for the EU.

Aston said discussions are underway with several pharmaceutical companies. When launched in the EU market, SUBA-Itraconazole will be competing in the European itraconazole market which is currently over US$120 million per year.”

He said SUBA-Itraconazole would be registed in the EU in 2010, following meeting with Sweden’s MPA and the UK’s medicines and healthcate products regulatory agency.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.